229 related articles for article (PubMed ID: 10499608)
21. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
22. Clinical and preclinical pharmacokinetics of raltitrexed.
Clarke SJ; Beale PJ; Rivory LP
Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
[TBL] [Abstract][Full Text] [Related]
23. ZD-9331 AstraZeneca.
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2000 Sep; 1(1):141-9. PubMed ID: 11249590
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
François E; Hebbar M; Bennouna J; Mayeur D; Perrier H; Dorval E; Martin C; Bourgeois H; Barthélemy P; Douillard JY
Oncology; 2005; 68(4-6):299-305. PubMed ID: 16020956
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
30. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
Rees C; Beale P; Trigo JM; Mitchell F; Jackman A; Smith R; Douglass E; Judson I
Clin Cancer Res; 2003 Jun; 9(6):2049-55. PubMed ID: 12796367
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
36. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 2000 Jul; 72(1):112-4. PubMed ID: 10979221
[No Abstract] [Full Text] [Related]
37. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
38. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
[TBL] [Abstract][Full Text] [Related]
39. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
